Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

As the number of patients with Alzheimer's disease (AD) increases, it brings great suffering
to their families and causes a heavy socioeconomic burden to society. A vast amount of …

ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Astrocytes contribute to the complex cellular pathology of Alzheimer's disease (AD).
Neurons and astrocytes function in close collaboration through neurotransmitter recycling …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …

With the exception of a few monogenic forms, Alzheimer disease (AD) has a complex
aetiology that is likely to involve multiple susceptibility genes and environmental factors. The …

Although women experience significantly higher tau burden and increased risk for
Alzheimer's disease (AD) than men, the underlying mechanism for this vulnerability has not …

Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …

In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …